SCHEMBL18522656

SCHEMBL18522656

CC1(C)OCC(CCCCN2C(=O)c3ccccc3C2=O)O1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP2C9 P11712 1/20 0.52
ACHE P22303 1/20 0.46
TDP1 Q9NUW8 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAOB P27338 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.42
CHRM2 P08172 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20707236 1.00 CYP1A2 (0.52) CYP1A2CYP2C19CYP2C9ACHETDP1
SCHEMBL752923 0.96 CYP1A2 (0.56) CYP1A2CYP2C19CYP2C9ACHETDP1
SCHEMBL16392602 0.86 ACHE (0.52) ACHEMAOB
SCHEMBL7434719 0.82 ALDH1A1 (0.52) CYP1A2CYP2C19CYP2C9ACHEKDM4E
SCHEMBL12767468 0.81 RECQL (0.46) CYP1A2CYP2C19CYP2C9TDP1KDM4E
SCHEMBL12767504 0.81 RECQL (0.46) CYP1A2CYP2C19CYP2C9TDP1KDM4E
SCHEMBL8061487 0.81 TDP1 (0.51) CYP1A2CYP2C19CYP2C9TDP1KDM4E
SCHEMBL8070914 0.79 TDP1 (0.54) CYP1A2CYP2C19CYP2C9TDP1ALDH1A1
SCHEMBL8071862 0.79 TDP1 (0.54) CYP1A2CYP2C19CYP2C9TDP1ALDH1A1
SCHEMBL12253437 0.78 RAB9A (0.42) CYP1A2CYP2C19CYP2C9ACHETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11529423-B2 Biodegradable polyethylene glycol derivative having cyclic benzylidene acetal linker NOF CORPORATION (JP) 2022-12-20 US disclosed
US-11530295-B2 Hydrophilic polymer derivative having cyclic benzylidene acetal linker NOF CORPORATION (JP) 2022-12-20 US disclosed
US-11041052-B2 Biodegradable hydrogel having cyclic benzylidene acetal structure NOF CORPORATION (JP) 2021-06-22 US disclosed
EP-3130587-B1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORP (JP) 2021-06-16 EP disclosed
EP-3357514-B1 LIPID DERIVATIVE IN WHICH HYDROPHILIC POLYMER IS BOUND VIA CYCLIC BENZYLIDENE ACETAL LINKERS NOF CORP (JP) 2021-04-14 EP disclosed
EP-3279236-B1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORP (JP) 2021-01-06 EP disclosed
US-10808050-B2 Antibody-drug conjugate having cyclic benzylidene acetal linker NOF CORPORATION (JP) 2020-10-20 US disclosed
US-20200291178-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2020-09-17 US disclosed
US-20200289656-A1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2020-09-17 US disclosed
US-10626217-B2 Lipid derivative in which hydrophilic polymer is bound through cyclic benzylidene acetal linker NOF CORPORATION (JP) 2020-04-21 US disclosed
US-20190092906-A1 BIODEGRADABLE HYDROGEL HAVING CYCLIC BENZYLIDENE ACETAL STRUCTURE NOF CORPORATION (JP) 2019-03-28 US disclosed
EP-3357514-A1 LIPID DERIVATIVE IN WHICH HYDROPHILIC POLYMERS ARE BOUND VIA CYCLIC BENZYLIDENE ACETAL LINKERS NOF Corporation (JP) 2018-08-08 EP disclosed
US-20180078651-A1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2018-03-22 US disclosed
US-20180078651-A1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2018-03-22 US disclosed
US-20170290919-A1 ANTIBODY-DRUG CONJUGATE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2017-10-12 US disclosed
US-20170290919-A1 ANTIBODY-DRUG CONJUGATE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2017-10-12 US disclosed
EP-3210623-A1 ANTIBODY-DRUG COMPLEX HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF Corporation (JP) 2017-08-30 EP disclosed
US-20170107325-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2017-04-20 US disclosed
US-20170107325-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF CORPORATION (JP) 2017-04-20 US disclosed
EP-3130587-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER NOF Corporation (JP) 2017-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291178-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER H1-2, H1-0, H1-3 CYP1A2 3131/4885CYP2C19 3364/4885CYP2C9 4149/4885
US-11529423-B2 Biodegradable polyethylene glycol derivative having cyclic benzylidene acetal linker AMDHD2, PGD, TREH CYP1A2 2041/4885CYP2C19 853/4885CYP2C9 1979/4885
US-10626217-B2 Lipid derivative in which hydrophilic polymer is bound through cyclic benzylidene acetal linker SGMS1, SGMS2, CERT1 CYP1A2 1420/4885CYP2C19 1921/4885CYP2C9 2772/4885
US-10808050-B2 Antibody-drug conjugate having cyclic benzylidene acetal linker H1-2, CD22, H1-0 CYP1A2 1026/4885CYP2C19 766/4885CYP2C9 1120/4885
US-20180078651-A1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER AMDHD2, PGD, TREH CYP1A2 2041/4885CYP2C19 853/4885CYP2C9 1979/4885
US-11041052-B2 Biodegradable hydrogel having cyclic benzylidene acetal structure H1-0, H1-2, H1-4 CYP1A2 1454/4885CYP2C19 1670/4885CYP2C9 1631/4885
US-20170290919-A1 ANTIBODY-DRUG CONJUGATE HAVING CYCLIC BENZYLIDENE ACETAL LINKER H1-2, CD22, H1-0 CYP1A2 1026/4885CYP2C19 766/4885CYP2C9 1120/4885
US-11530295-B2 Hydrophilic polymer derivative having cyclic benzylidene acetal linker H1-2, H1-0, H1-3 CYP1A2 3131/4885CYP2C19 3364/4885CYP2C9 4149/4885
US-20200289656-A1 BIODEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER AMDHD2, PGD, TREH CYP1A2 2041/4885CYP2C19 853/4885CYP2C9 1979/4885
US-20170107325-A1 HYDROPHILIC POLYMER DERIVATIVE HAVING CYCLIC BENZYLIDENE ACETAL LINKER H1-2, H1-0, H1-3 CYP1A2 3117/4885CYP2C19 3310/4885CYP2C9 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.